BiotechTube

Benralizumab + Matching placebo

Phase 3Terminated
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Eosinophilic Esophagitis

Conditions

Eosinophilic Esophagitis

Trial Timeline

Sep 22, 2020 → Feb 6, 2023

NCT ID
NCT04543409

About Benralizumab + Matching placebo

Benralizumab + Matching placebo is a phase 3 stage product being developed by AstraZeneca for Eosinophilic Esophagitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04543409. Target conditions include Eosinophilic Esophagitis.

What happened to similar drugs?

6 of 16 similar drugs in Eosinophilic Esophagitis were approved

Approved (6) Terminated (1) Active (9)
🔄Tezepelumab + TezepelumabAstraZenecaPhase 3
✅BenralizumabAstraZenecaApproved
🔄BenralizumabAstraZenecaPhase 3
🔄Benralizumab + Mepolizumab + Placebo to Mepolizumab + Placebo to BenralizumabAstraZenecaPhase 3
✅Benralizumab Prefilled SyringeAstraZenecaApproved
🔄Benralizumab + PlaceboAstraZenecaPhase 3
🔄BenralizumabAstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04543409Phase 3Terminated

Competing Products

20 competing products in Eosinophilic Esophagitis

See all competitors
ProductCompanyStageHype Score
KHK4563 + KHK4563 + KHK4563 + PlaceboKyowa KirinPhase 2
35
benralizumab + benralizumab + PlaceboKyowa KirinPhase 2
35
SHR-1703 + SHR-1703 PlaceboJiangsu Hengrui MedicinePhase 2
35
NS-229 + PlaceboNippon ShinyakuPhase 2
42
Esomeprazole + BudesonideAstraZenecaPhase 2/3
38
Tezepelumab + TezepelumabAstraZenecaPhase 3
44
BenralizumabAstraZenecaApproved
43
CohortAstraZenecaPre-clinical
26
BenralizumabAstraZenecaPhase 3
44
Benralizumab + Mepolizumab + Placebo to Mepolizumab + Placebo to BenralizumabAstraZenecaPhase 3
44
Benralizumab Prefilled SyringeAstraZenecaApproved
50
benralizumabAstraZenecaPre-clinical
33
Benralizumab + PlaceboAstraZenecaPhase 3
44
BenralizumabAstraZenecaPhase 3
47
Benralizumab + PlaceboAstraZenecaPhase 3
32
Tezepelumab + PlaceboAstraZenecaPhase 2
42
Benralizumab + PlaceboAstraZenecaPhase 2/3
38
inhaled/swallowed budesonide + viscous/swallowed budesonideAstraZenecaPre-clinical
26
Benralizumab + 129 XenonAstraZenecaPre-clinical
30
Benralizumab + PlaceboAstraZenecaPhase 3
40